Priority Healthcare Selected as a Provider of Ventavis(TM)

Priority Healthcare Selected as a Provider of Ventavis(TM) 


LAKE MARY, Fla., Feb. 22  /PRNewswire-FirstCall/ -- Priority Healthcare
Corporation (NASDAQ:PHCC) announced that it has been selected by CoTherix, Inc.
(NASDAQ:CTRX) to be a full-service specialty pharmacy provider of Ventavis(TM)
(iloprost) Inhalation Solution.  The Food and Drug Administration approved
Ventavis(TM) on December 29, 2004 for the treatment of pulmonary arterial
hypertension (World Health Organization Group I) or PAH, in patients with NYHA
Class III or IV symptoms.

"We are pleased to have been selected by CoTherix as one of the limited network
of specialty pharmacies that will have access to Ventavis," stated Steve
Cosler, President and CEO.  "Adding this important product to our growing
portfolio of treatment options for PAH patients facilitates better continuity
of care for the patients and physicians involved with this community.  This
patient population requires a high degree of nursing support which we are able
to provide through our 29 pharmacy locations nationwide."

Physicians prescribing Ventavis for their patients can call Priority
Healthcare's dedicated pulmonary hypertension call center at 866-4PH-TEAM to
receive a comprehensive reimbursement profile for their patients and other
clinical support services that are provided as part of the Priority Healthcare
CaringPath(SM) disease management program for PAH.

IMPORTANT SAFETY INFORMATION: In clinical studies, common adverse reactions due
to Ventavis included: vasodilation (flushing), cough, headache, flu syndrome,
nausea, trismus, hypotension, insomnia and syncope. Because of the risk of
syncope, vital signs should be monitored while initiating Ventavis. Dose
adjustments or a change in therapy should be considered if exertional syncope
occurs. Ventavis should not be initiated in patients with systolic blood
pressure lower than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary
edema occur. Ventavis has not been evaluated in patients with chronic
obstructive pulmonary disease (COPD), severe asthma, or with acute pulmonary
infections.

About Priority Healthcare Corporation

Priority Healthcare Corporation is a national specialty pharmacy and
distributor that provides biopharmaceuticals, complex therapies, and related
disease treatment services.  Priority Healthcare provides comprehensive
programs for patients, payors, physicians, and pharmaceutical manufacturers for
a growing number of disease states including cancer, hepatitis C, respiratory
and pulmonary conditions, infertility, rheumatoid arthritis, hemophilia,
multiple sclerosis, Parkinson's disease, and macular degeneration. Additional
information regarding Priority Healthcare is available online at
http://www.priorityhealthcare.com/

Certain statements included in this press release, which are not historical
facts, are forward-looking statements.  Such forward-looking statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.  These forward-looking statements represent our
expectations or beliefs and involve certain risks and uncertainties, including
those described in our public filings with the United States Securities and
Exchange Commission; also including, but not limited to, changes in interest
rates, competitive pressures, changes in customer mix, changes in third party
reimbursement rates, financial stability of major customers, changes in
government regulations or the interpretation of these regulations, changes in
supplier relationships, growth opportunities, cost savings, revenue
enhancements, synergies and other benefits anticipated from acquisition
transactions, difficulties relative to integrating acquired businesses, the
accounting and tax treatment of acquisitions, and asserted and unasserted
claims, which could cause actual results to differ from those in the
forward-looking statements.  The forward-looking statements by their nature
involve substantial risks and uncertainties, certain of which are beyond our
control, and actual results may differ materially depending on a variety of
important factors.  You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date herein. 

http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGODATASOURCE: Priority
Healthcare Corporation



CONTACT:  Stephen Saft, Chief Financial Officer of Priority Healthcare

Corporation, [phone]



Web site:  http://www.priorityhealthcare.com/ 

Copyright